{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:36:01Z","timestamp":1793111761166,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40263-025-01233-0","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:51:29Z","timestamp":1759218689000},"page":"71-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Estimating Changes in Clinical Outcomes after Discontinuation of Anti-CGRP Targeting Therapy for Migraine Prophylaxis: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8728-1411","authenticated-orcid":false,"given":"Luana Miyahira","family":"Makita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-9913","authenticated-orcid":false,"given":"Thales Pardini","family":"Fagundes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3406-0770","authenticated-orcid":false,"given":"Pedro Henrique","family":"Reginato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1454-1450","authenticated-orcid":false,"given":"Lucca Passow","family":"Carpinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9068-1008","authenticated-orcid":false,"given":"Giovanna","family":"de Freitas Morais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-8443","authenticated-orcid":false,"given":"Renata Trinkel","family":"Montanarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9357-6381","authenticated-orcid":false,"given":"Rafael","family":"de Freitas Kleimmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6155-4006","authenticated-orcid":false,"given":"Rafael Eduardo","family":"Streit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5737-4474","authenticated-orcid":false,"given":"Aishwarya","family":"Koppanatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6513-2408","authenticated-orcid":false,"given":"Andressa Christine Sales","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elcio Juliato","family":"Piovesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"4","key":"1233_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"JD Steinmetz","year":"2024","unstructured":"Steinmetz JD, Seeher KM, Schiess N, et al. Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344\u201381.","journal-title":"Lancet Neurol"},{"key":"1233_CR2","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"issue":"8","key":"1233_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, et al. Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2019;59(8):1286\u201399.","journal-title":"Headache"},{"issue":"1","key":"1233_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jpain.2016.10.005","volume":"18","author":"AD Raval","year":"2017","unstructured":"Raval AD, Shah A. National trends in direct health care expenditures among US adults with migraine: 2004 to 2013. J Pain. 2017;18(1):96\u2013107.","journal-title":"J Pain"},{"issue":"7","key":"1233_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021\u201339.","journal-title":"Headache"},{"issue":"4","key":"1233_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644\u201355.","journal-title":"Headache"},{"issue":"10210","key":"1233_CR7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","volume":"394","author":"A Charles","year":"2019","unstructured":"Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019;394(10210):1765\u201374.","journal-title":"Lancet"},{"key":"1233_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231159366","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023. https:\/\/doi.org\/10.1177\/03331024231159366.","journal-title":"Cephalalgia"},{"issue":"5","key":"1233_CR9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815\u201332.","journal-title":"Cephalalgia"},{"issue":"10","key":"1233_CR10","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40(10):1026\u201344.","journal-title":"Cephalalgia"},{"issue":"7","key":"1233_CR11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0333102411398400","volume":"31","author":"M Lant\u00e9ri-Minet","year":"2011","unstructured":"Lant\u00e9ri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837\u201350.","journal-title":"Cephalalgia"},{"issue":"4\u20135","key":"1233_CR12","first-page":"326","volume":"42","author":"B Raffaelli","year":"2021","unstructured":"Raffaelli B, Terhart M, Overeem LH, et al. Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia. 2021;42(4\u20135):326\u201334.","journal-title":"Cephalalgia"},{"issue":"6","key":"1233_CR13","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1007\/s10072-022-05870-x","volume":"43","author":"S Guerzoni","year":"2022","unstructured":"Guerzoni S, Baraldi C, Pensato U, et al. Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. Neurol Sci. 2022;43(6):3823\u201330.","journal-title":"Neurol Sci"},{"key":"1233_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1009-9","author":"P Martelletti","year":"2019","unstructured":"Martelletti P, Edvinsson L, Ashina M. Shaping the future of migraine targeting calcitonin-gene-related-peptide with the disease-modifying migraine drugs (DMMDs). J Headache Pain. 2019. https:\/\/doi.org\/10.1186\/s10194-019-1009-9.","journal-title":"J Headache Pain"},{"key":"1233_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s42451-020-00163-z","volume":"3","author":"HC Diener","year":"2020","unstructured":"Diener HC. Prophylaxe Der Migr\u00e4ne Mit Monoklonalen Antik\u00f6rpern Gegen CGRP Oder Den CGRP-Rezeptor, Erg\u00e4nzung Der S1-Leitlinie Therapie Der Migr\u00e4neattacke Und Prophylaxe Der Migr\u00e4ne: Zusammenfassung Der Empfehlungen Der DGN Und DMKG. DGNeurol. 2020;3:124\u20138.","journal-title":"DGNeurol"},{"key":"1233_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0955-y","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019. https:\/\/doi.org\/10.1186\/s10194-018-0955-y.","journal-title":"J Headache Pain"},{"issue":"6","key":"1233_CR17","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s40120-023-00550-0","volume":"12","author":"T Alsaadi","year":"2023","unstructured":"Alsaadi T, Kayed DM, Al-Madani A, et al. Consensus-based recommendations on the use of CGRP-based therapies for migraine prevention in the UAE. Neurol Ther. 2023;12(6):1845\u201365.","journal-title":"Neurol Ther"},{"key":"1233_CR18","doi-asserted-by":"publisher","DOI":"10.3122\/osf.io\/v7gm2","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie J, Bossuyt P, The PRISMA, et al. Statement: an updated guideline for reporting systematic reviews. Cent Open Sci. 2020. https:\/\/doi.org\/10.3122\/osf.io\/v7gm2.","journal-title":"Cent Open Sci"},{"key":"1233_CR19","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Training. https:\/\/training.cochrane.org\/handbook\/current. Accessed 19 Dec 2024."},{"key":"1233_CR20","unstructured":"CombineMeanSD. https:\/\/www.statstodo.com\/CombineMeansSDs.php. Accessed 19 Dec 2024."},{"key":"1233_CR21","unstructured":"automeris.io: computer vision assisted data extraction from charts using WebPlotDigitizer. https:\/\/automeris.io\/wpd\/. Accessed 19 Dec 2024."},{"key":"1233_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1233_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"1","key":"1233_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2020","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2020;12(1):55\u201361.","journal-title":"Res Synth Methods"},{"issue":"11\u201312","key":"1233_CR25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/03331024211014616","volume":"41","author":"AR Gantenbein","year":"2021","unstructured":"Gantenbein AR, Agosti R, Gobbi C, et al. Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment\u2014a real-life cohort study. Cephalalgia. 2021;41(11\u201312):1181\u20136.","journal-title":"Cephalalgia"},{"issue":"8","key":"1233_CR26","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.1007\/s00415-024-12470-6","volume":"271","author":"AR Gantenbein","year":"2024","unstructured":"Gantenbein AR, Bonvin C, Kamm CP, et al. Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results. J Neurol. 2024;271(8):5402\u201310.","journal-title":"J Neurol"},{"key":"1233_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2662","author":"M Nsaka","year":"2022","unstructured":"Nsaka M, Scheffler A, Wurthmann S, et al. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies. Brain Behav. 2022. https:\/\/doi.org\/10.1002\/brb3.2662.","journal-title":"Brain Behav"},{"key":"1233_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1018-8","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain. 2019. https:\/\/doi.org\/10.1186\/s10194-019-1018-8.","journal-title":"J Headache Pain"},{"issue":"3","key":"1233_CR29","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40120-024-00602-z","volume":"13","author":"T Takeshima","year":"2024","unstructured":"Takeshima T, Doi H, Ooba S, Tanji Y, Ozeki A, Komori M. Clinical evaluation after discontinuation of galcanezumab in Japanese patients with episodic and chronic migraine: analysis of a randomized, placebo-controlled trial and open-label extension study. Neurol Ther. 2024;13(3):697\u2013714.","journal-title":"Neurol Ther"},{"issue":"23","key":"1233_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12237329","volume":"12","author":"Y Tereshko","year":"2023","unstructured":"Tereshko Y, Dal Bello S, Pez S, et al. Comparative study of the efficacy of anti-CGRP mAbs on migraineurs: analysis of the first year of therapy, 1-month suspension period, and reprisal. J Clin Med. 2023;12(23):7329.","journal-title":"J Clin Med"},{"issue":"11","key":"1233_CR31","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1007\/s00415-023-11872-2","volume":"270","author":"F Vernieri","year":"2023","unstructured":"Vernieri F, Brunelli N, Guerzoni S, et al. Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study. J Neurol. 2023;270(11):5436\u201348. https:\/\/doi.org\/10.1007\/s00415-023-11872-2.","journal-title":"J Neurol"},{"key":"1233_CR32","doi-asserted-by":"publisher","DOI":"10.1212\/cpj.0000000000001112","author":"FS di Cola","year":"2021","unstructured":"di Cola FS, Caratozzolo S, Venturelli E, et al. Erenumab discontinuation after 12-month treatment. Neurol Clin Pract. 2021. https:\/\/doi.org\/10.1212\/cpj.0000000000001112.","journal-title":"Neurol Clin Pract"},{"issue":"8","key":"1233_CR33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11916-024-01259-x","volume":"28","author":"S Cho","year":"2024","unstructured":"Cho S, Kim B. Long-term outcome after discontinuation of CGRP-targeting therapy for migraine. Curr Pain Headache Rep. 2024;28(8):743\u201351. https:\/\/doi.org\/10.1007\/s11916-024-01259-x.","journal-title":"Curr Pain Headache Rep"},{"key":"1233_CR34","unstructured":"AIPS. Einzelabfrage. https:\/\/www.swissmedicinfo.ch\/ViewMonographie. Accessed 19 Dec 2024."},{"key":"1233_CR35","unstructured":"Agenzia Italiana del Farmaco. Aimovig (erenumab) Indicazione rimborsata. https:\/\/www.aifa.gov.it\/documents\/20142\/1220805\/AIMOVIG_13821_INNOV._v.1.0.pdf. Accessed Nov 2018."},{"issue":"1","key":"1233_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18(1):101.","journal-title":"J Headache Pain"},{"key":"1233_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241269735","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia. 2024. https:\/\/doi.org\/10.1177\/03331024241269735.","journal-title":"Cephalalgia"},{"issue":"5","key":"1233_CR38","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716\u201325.","journal-title":"Eur J Neurol"},{"issue":"5","key":"1233_CR39","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1007\/s00415-024-12192-9","volume":"271","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Aurilia C, Egeo G, et al. Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. insights from the multicenter, prospective, I-GRAINE study. J Neurol. 2024;271(5):2605\u201314.","journal-title":"J Neurol"},{"key":"1233_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01417-9","author":"B Raffaelli","year":"2022","unstructured":"Raffaelli B, Terhart M, Mecklenburg J, et al. Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience. J Headache Pain. 2022. https:\/\/doi.org\/10.1186\/s10194-022-01417-9.","journal-title":"J Headache Pain"},{"key":"1233_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01539-8","author":"L Al-Hassany","year":"2023","unstructured":"Al-Hassany L, Lyons HS, Boucherie DM, et al. The sense of stopping migraine prophylaxis. J Headache Pain. 2023. https:\/\/doi.org\/10.1186\/s10194-023-01539-8.","journal-title":"J Headache Pain"},{"issue":"12","key":"1233_CR42","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1007\/s00415-023-11880-2","volume":"270","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Buse DC, Nahas SJ, et al. Risk factors for migraine disease progression: a narrative review for a patient-centered approach. J Neurol. 2023;270(12):5692\u2013710.","journal-title":"J Neurol"},{"issue":"8","key":"1233_CR43","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1007\/s10072-020-05022-z","volume":"42","author":"E De Matteis","year":"2021","unstructured":"De Matteis E, Affaitati G, Frattale I, et al. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci. 2021;42(8):3297\u2013303.","journal-title":"Neurol Sci"},{"issue":"1","key":"1233_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01368-7","volume":"22","author":"M Terhart","year":"2021","unstructured":"Terhart M, Mecklenburg J, Neeb L, et al. Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain. 2021;22(1):158.","journal-title":"J Headache Pain"},{"issue":"1","key":"1233_CR45","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s10194-024-01850-y","volume":"25","author":"YC An","year":"2024","unstructured":"An YC, Hung KS, Liang CS, et al. Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population. J Headache Pain. 2024;25(1):149.","journal-title":"J Headache Pain"},{"issue":"9","key":"1233_CR46","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/head.13156","volume":"57","author":"JM Cohen","year":"2017","unstructured":"Cohen JM, Dodick DW, Yang R, et al. Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines. Headache. 2017;57(9):1375\u201384.","journal-title":"Headache"},{"issue":"2","key":"1233_CR47","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021;10(2):809\u201326.","journal-title":"Pain Ther"},{"key":"1233_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnab093","author":"F Cohen","year":"2021","unstructured":"Cohen F, Armand C, Lipton RB, Vollbracht S. Efficacy and tolerability of calcitonin gene\u2013related peptide\u2013targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxinA in patients with chronic migraine. Pain Med. 2021. https:\/\/doi.org\/10.1093\/pm\/pnab093.","journal-title":"Pain Med"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01233-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01233-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01233-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:07:55Z","timestamp":1767611275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01233-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01233-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"This study did not involve the development or use of custom code. All analyses were conducted using standard statistical software and publicly available packages.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"No datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Conception and design: L.M.M., R.F.K., and E.J.P. Acquisition of data: L.M.M., L.P.C., G.F.M., R.T.M., and A.C.R.S. Analysis and interpretation of data: P.H.R., R.E.S., and A.K. Drafting the manuscript: L.M.M. and T.P.F. Revising for intellectual content: T.P.F., L.P.C., R.E.S., and E.J.P. All authors have read and approved the final manuscript and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contributions"}}]}}